{"entity":{"id":"nct03869892","kind":"trial","name":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","aka":["SOLSTICE"],"tldr":"A phase 3 trial of capecitabine in colorectal cancer, run by Institut de Recherches Internationales Servier, active but no longer recruiting.","summary":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. is a phase 3, randomised interventional study registered as NCT03869892 by Institut de Recherches Internationales Servier, with a registry enrolment figure of 856 participants, started 2019-03-21 and due to reach its primary completion in 2021-06-29. Interventions recorded: Trifluridine/tipiracil hydrochloride (S95005); Capecitabine; Bevacizumab experimental; Bevacizumab control. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Progression-free Survival (PFS). Colorectal eligibility wording from the registry: \"Has definitive histologically confirmed adenocarcinoma of the colon or rectum (all other histological types are excluded)\". Sites: Argentina, Australia, Austria, Brazil, Bulgaria, Czechia, Denmark, Estonia, France, Germany, Hungary, Ireland and 13 more countries. United Kingdom sites listed: 11. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03869892","url":"https://clinicaltrials.gov/study/NCT03869892"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Aberdeen Royal Infirmary Oncology Department (Aberdeen); University Hospitals Bristol Bristol Haematology & Oncology Centre (Bristol); St James's University Hospital (Leeds); Leicester Royal Infirmary The HOPE Clinical Trials Unit (Leicester); Royal Marsden Hospital Department of Medicine (London); Hammersmith Hospital Gary Weston Centre (London); Sarah Cannon Research Institute UK Clinical Trials (London); Imperial Healthcare NHS Trust Charing Cross Hospital (London); Christie Hospital NHS Foundation Trust GI & Endocrine (Manchester); Glan Clwyd Hospital North Wales Cancer Treatment Centre (Rhyl); Royal Marsden Hospital Department of Medicine (Sutton)."],"nct":"NCT03869892","phase":"3","setting":"An Open-label, Randomised, Phase III Study cOmparing trifLuridine/Tipiracil (S 95005) in Combination With Bevacizumab to Capecitabine in Combination With Bevacizumab in firST-line Treatment of Patients With metastatIC Colorectal Cancer Who Are Not candidatE for Intensive Therapy (SOLSTICE Study)","sponsor":"Institut de Recherches Internationales Servier","enrolled":856,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03869892/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}